Testing effectiveness (Phase 2)Study completedNCT02949830
What this trial is testing
Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
Who this might be right for
Acute Intermittent Porphyria
Alnylam Pharmaceuticals 16